Table 3.
Univariate and multivariate analysis of overall survival for patients with recurrence after two-stage hepatectomy
| Variable | N(%) | 5-year survival rate, % |
Univariate P value |
Hazard ratio |
95% confidence interval |
Multivariate P value |
|---|---|---|---|---|---|---|
| All patients | 83 | 42 | ||||
| Preoperative factors | ||||||
| Age, >60 years | 55 (66) | 47 | 0.798 | |||
| Preoperative chemotherapy | 82 (99) | 41 | 0.110 | |||
| Rectal primary tumor | 30 (36) | 37 | 0.264 | |||
| Positive primary tumor nodal status |
63 (75) | 46 | 0.569 | |||
| Synchronous presentation | 72 (87) | 41 | 0.929 | |||
| Extra-hepatic disease | 16 (19) | 38 | 0.764 | |||
| Histopathologic factors | ||||||
| Total number of tumors > 5 | 51 (61) | 33 | 0.306 | |||
| Largest tumor diameter > 5 cm | 18 (22) | 33 | 0.817 | |||
| Positive surgical margin at either stage of TSH |
29 (35) | 39 | 0.900 | |||
| Complete pathologic response | 11 (15) | 44 | 0.665 | |||
| RAS mutation | 36 (46) | 19 | 0.006 | 2.25 | 1.16–4.50 | 0.016 |
| Postoperative factors | ||||||
| Portal vein embolization | 59 (71) | 40 | 0.980 | |||
| Interval chemotherapy | 31 (37) | 28 | 0.994 | |||
| Major complication at either Stage of TSH |
19 (23) | 34 | 0.287 | |||
| Adjuvant chemotherapy | 54 (70) | 44 | 0.973 | |||
| Recurrence-related factors | ||||||
| First recurrence at multiple sites | 25 (30) | 24 | 0.005 | 2.28 | 1.17–4.37 | 0.016 |
| Resection for recurrence | 31 (37) | 67 | <0.001 | 0.25 | 0.10–0.54 | <0.001 |
| TSH, two-stage hepatectomy | ||||||